## SEQUENCE LISTING

<110> ONCOTHERAPY SCIENCE, INC. JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOK	YO
<120> Method for cell injuring using effector function of anti FAM3D a	ıntibody.
<130> ONC-A0407-US	
<160> 2	
<170> PatentIn version 3.1	
<210> 1	
<211> 1322	
<212> DNA	
<213> Homo sapiens	
⟨220⟩	
<221> CDS	
<b>⟨222⟩</b> (298) (972)	
⟨223⟩	
<400> 1	
tcctcaaagg aggggcagag cctgcgcagg gcaggagcag ctggcccact ggcggcccgc	60
aacactccgt ctcaccctct gggcccactg catctagagg agggccgtct gtgaggccac	120
tacccctcca gcaactggga ggtgggactg tcagaagctg gcccagggtg gtggtcagct	180
gggtcaggga cctacggcac ctgctggacc acctcgcctt ctccatcgaa gcagggaagt	240
gggagcctcg agccctcggg tggaagctga ccccaagcca cccttcacct ggacagg	297
atg aga gtg tca ggt gtg ctt cgc ctc ctg gcc ctc atc ttt gcc ata	345
Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile	
1 5 10 15	
gic acg aca igg aig iii aii cga agc iac aig agc iic agc aig aaa	393
Val Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys	
20 25 30	
acc atc cgt ctg cca cgc tgg ctg gca gcc tcg ccc acc aag gag atc	441
Thr Ile Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile	
35 40 45	

									aag Lys						489
									gcc Ala 75						537
	_								agt Ser						585
								Val	aat Asn				Gly		633
							Met		tct Ser			Val			681
						Ile			ggt Gly		Leu				729
_					Gly				aac Asn 155	Asp					777
		Asp		Gly	Ser	Ser		Ala	aaa Lys )					Arg	825
			Phe					Asp	ctc Leu				Ser		873
		Phe					Pro		aca Thr			Tyr		gga Gly	921
									atg Met						969

1022

1082

1142

1202 1262

1322

220 215 210 tag ggtggctgtg gctcttcctc agccaggggc ctgaagaagc tcctgcctga cttaggagtc agagcccggc aggggctgag gaggaggagc agggggtgct gcgtggaagg tgctgcaggt ccttgcacgc tgtgtcgcgc ctctcctcct cggaaacaga accctcccac agcacatect acceggaaga ceagecteag agggteette tggaaceage tgtetgtgga gagaatgggg tgctttcgtc agggactgct gacggctggt cctgaggaag gacaaactgc ccagactiga gcccaattaa attitattit tgctggttit gaatgaaaaa aaaaaaaaaa <210> 2 **<211> 224** <212> PRT <213> Homo sapiens <400> 2 Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile 5 10 15 Val Thr Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys 30 20 25 Thr lle Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile 45 35 40 Gln Val Lys Lys Tyr Lys Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn 50 55 60 Tyr Phe Ala Phe Lys Ile Cys Ser Gly Ala Ala Asn Val Val Gly Pro 80 65 70 75 Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys Asn Asn 85 Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr Gly Ala 105 100

Val Leu Gly Gln Lys Ala Phe Asp Met Tyr Ser Gly Asp Val Met His

Leu Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val

120

115

125

130	135	140

Ala Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys
145 150 155 160

Leu Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg 165 170 175

Asp Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro 180 185 190

Phe Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly 195 200 205

Trp Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe 210 215 220